These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 594750)

  • 1. [Treatment of Raynaud's syndrome].
    Cloarec M; Cristol R; Graisely B
    Sem Hop Ther; 1977; 53(7-8):357-62. PubMed ID: 594750
    [No Abstract]   [Full Text] [Related]  

  • 2. [The vasoprostan treatment of patients with Raynaud's syndrome].
    Alekperov RT; Mach ES; Guseva NG
    Ter Arkh; 1997; 69(8):22-3. PubMed ID: 9381386
    [No Abstract]   [Full Text] [Related]  

  • 3. Sildenafil for the treatment of Raynaud's phenomenon.
    Heymann WR
    J Am Acad Dermatol; 2006 Sep; 55(3):501-2. PubMed ID: 16908357
    [No Abstract]   [Full Text] [Related]  

  • 4. Vasodilator refractoriness in Raynaud's syndrome.
    Sarkany I; Tan OT; Gaylarde PM
    Clin Exp Dermatol; 1982 Nov; 7(6):679-80. PubMed ID: 7151321
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al.
    Lichtenstein JR
    Arthritis Rheum; 2003 Jan; 48(1):282-3; author reply 283. PubMed ID: 12528146
    [No Abstract]   [Full Text] [Related]  

  • 6. Medical treatment in Raynaud's disease.
    Hansteen V
    Acta Chir Scand Suppl; 1976; 465():87-91. PubMed ID: 793268
    [No Abstract]   [Full Text] [Related]  

  • 7. Recount of prostaglandin E1 therapy in a patient with Raynaud's phenomenon.
    DiGiovanni RL; Littlefield JM; Good RG
    J Am Osteopath Assoc; 1995 Oct; 95(10):572. PubMed ID: 8557544
    [No Abstract]   [Full Text] [Related]  

  • 8. [Capilloroscopy of nail folds in Raynaud's syndrome during Hypacom treatment].
    Bendkowski W; Bogdanowski T
    Pol Tyg Lek; 1978 Oct; 33(41):1619-20. PubMed ID: 704471
    [No Abstract]   [Full Text] [Related]  

  • 9. Raynaud's (primary).
    Pope J
    Clin Evid; 2003 Dec; (10):1444-53. PubMed ID: 15555156
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of Raynaud's phenomenon].
    Levy Y; Shoenfeld Y
    Harefuah; 1993 Mar; 124(5):288-91. PubMed ID: 8098699
    [No Abstract]   [Full Text] [Related]  

  • 11. Raynaud's phenomenon (primary).
    Pope J
    Clin Evid; 2005 Jun; (13):1546-54. PubMed ID: 16135302
    [No Abstract]   [Full Text] [Related]  

  • 12. Raynaud's phenomenon (primary).
    Pope J
    Clin Evid; 2004 Dec; (12):1725-34. PubMed ID: 15865744
    [No Abstract]   [Full Text] [Related]  

  • 13. [Recent advances in Raynaud's syndrome].
    Klein-Weigel P
    Dtsch Med Wochenschr; 2012 Mar; 137(13):622-4. PubMed ID: 22434167
    [No Abstract]   [Full Text] [Related]  

  • 14. [Spasm and Raynaud's phenomenon].
    Fiessinger JN
    Ann Cardiol Angeiol (Paris); 1981; 30(2):91-3. PubMed ID: 7259052
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome.
    Ring EF; Porto LO; Bacon PA
    J Int Med Res; 1981; 9(6):393-400. PubMed ID: 7319129
    [No Abstract]   [Full Text] [Related]  

  • 16. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raynaud's phenomenon (primary).
    Pope J
    Clin Evid; 2003 Jun; (9):1339-48. PubMed ID: 12967424
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
    Gore J; Silver R
    Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
    [No Abstract]   [Full Text] [Related]  

  • 19. Reserpine in Raynaud's phenomenon.
    Lancet; 1970 Aug; 2(7670):454. PubMed ID: 4195127
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?
    Hughes M; Khanna D; Pauling JD
    Rheumatology (Oxford); 2020 Mar; 59(3):464-466. PubMed ID: 31670800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.